Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
86
K
Drugs & Biologics
46
K
Targets
977
K
Organizations
922
K
/
171
K
Clinical Trials / Results
66
M
Literatures
16
M
Patents
Recent blog posts
View all blog posts →
Hanmi collaborates clinically and signs supply deal with MSD to test BH3120 along with KEYTRUDA® (pembrolizumab)
Latest Hotspot
3 min read
Hanmi collaborates clinically and signs supply deal with MSD to test BH3120 along with KEYTRUDA® (pembrolizumab)
26 April 2024
Hanmi Pharmaceutical will start a phase 1 clinical trial to evaluate the safety and effectiveness of its cancer immunotherapy, ‘BH3120’, in combination with MSD's KEYTRUDA® (pembrolizumab).
Read →
BeiGene Secures EC Nod for Tislelizumab in Treating Non-Small Cell Lung Cancer
Latest Hotspot
3 min read
BeiGene Secures EC Nod for Tislelizumab in Treating Non-Small Cell Lung Cancer
26 April 2024
BeiGene, Ltd. disclosed that tislelizumab has received approval from the European Commission for use in treating non-small cell lung cancer.
Read →
Initial Dosing in Phase I Glioblastoma Trial by ITM, Helmholtz Munich, and University Hospital Münster
Latest Hotspot
3 min read
Initial Dosing in Phase I Glioblastoma Trial by ITM, Helmholtz Munich, and University Hospital Münster
25 April 2024
ITM, Helmholtz Munich, and University Hospital Münster Report Initial Dosing of First Participant in Phase I Research Trial for Glioblastoma.
Read →
Check out our latest report
View all reports →
Global Drug R&D Express (Jan 2024)

Global Drug R&D Express (Jan 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 68 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Dec 2023)

Global Drug R&D Express (Dec 2023)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 104 drugs. Among them, 2 first-to-market drugs and 5 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Nov 2023)

Global Drug R&D Express (Nov 2023)

This report compiles and summarizes the basic information of all the first-to-market and special-review medicines globally in November, totaling 104. From these, 5 first-to-market medicines and 5 special-review medicines have been meticulously selected. The report provides a detailed interpretation of these medicines, covering multiple aspects such as their basic information, development status, technological barriers, mechanisms of action, clinical trials, and competitive landscape.

Read →
Latest news
View all news →
news cover
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
16 hours ago
news cover
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
16 hours ago
news cover
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
17 hours ago
news cover
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
21 hours ago
Who We Serve
View our solutions →
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
LifeScience Product Suite
Synapse
Looking for drug development opportunities
Evaluate the value of license-in projects
Screen investment targets
Optimize product pipeline
Current product
Bio
Chase new frontiers in bio-innovation
Stay on top of competitor movements
Validate novelty and freedom to operate searches with ease
Identify sequences for therapeutic activities
View details
Chemical
Explore promising compounds and their applications
Accelerate novelty and freedom to operate reviews
Strengthen competitor analysis
View details
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.